Compare AbbVie Inc (ABBV) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ABRDN Physical Gold Shares ETF — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while ABRDN Physical Gold Shares ETF trades at $38.63. The key difference: AbbVie Inc pays a 2.72% dividend while ABRDN Physical Gold Shares ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SGOL | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $51.41 |
52-Week Low | $184.85 | $31.18 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
SGOL, a US-listed gold ETF, trades at $39.65, up 1.04% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights central bank gold buying and shifting Fed rate expectations as key drivers. The stock lacks fundamental ratios like P/E and P/B, typical for commodity ETFs tracking physical gold prices rather than corporate earnings.
The outlook for SGOL hinges on gold's safe-haven appeal amid economic uncertainty, with analysts forecasting potential price gains to $4,600-$5,500 per ounce by 2027. Risks include Fed policy shifts, dollar strength, and volatility from geopolitical events. Investor sentiment is cautiously optimistic due to institutional accumulation and ETF inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
